AKTIS ONCOLOGY
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.
AKTIS ONCOLOGY
Industry:
Biotechnology Health Care Life Science Oncology
Founded:
2021-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.aktisoncology.com
Total Employee:
11+
Status:
Active
Total Funding:
156 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Global Site Tag Sitelinks Search Box Google Analytics 4 Yoast WordPress SEO Plugin
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Fore Biotherapeutics
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Oncora Medical
Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Investors List
Eli Lilly
Eli Lilly investment in Corporate Round - Aktis Oncology
Vida Ventures
Vida Ventures investment in Series A - Aktis Oncology
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series A - Aktis Oncology
Merck
Merck investment in Series A - Aktis Oncology
Mirae Asset Venture Investment
Mirae Asset Venture Investment investment in Series A - Aktis Oncology
MPM Capital
MPM Capital investment in Series A - Aktis Oncology
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Series A - Aktis Oncology
TCG Crossover
TCG Crossover investment in Series A - Aktis Oncology
MRL Ventures Fund
MRL Ventures Fund investment in Series A - Aktis Oncology
Novartis
Novartis investment in Series A - Aktis Oncology
Official Site Inspections
http://www.aktisoncology.com Semrush global rank: 7.11 M Semrush visits lastest month: 890
- Host name: 79.148.83.34.bc.googleusercontent.com
- IP address: 34.83.148.79
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Aktis Oncology"
Our Team | Aktis Oncology
The Aktis Oncology team is pioneering the discovery and development of targeted radiopharmaceuticals to treat a broad range of solid tumors.See details»
Director, Total Rewards People Operations - aktisoncology.com
Www.aktisoncology.com disability, and leave management in a multi‐state environment. ... • Worked at a fast‐paced Biotech or Life Science organization, bringing credibility, energy and …See details»
Aktis Oncology - Crunchbase Company Profile & Funding
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.See details»
Aktis Oncology - LinkedIn
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.See details»
Aktis Oncology Company Profile 2024: Valuation, …
Aktis Oncology General Information Description. Developer of a targeted radiopharmaceutical designed to treat a broad range of solid tumor cancers. The company's radiopharmaceuticals generate cells-targeting agents with ideal …See details»
Aktis Oncology, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Story AbbVie's R&D org changes hands AbbVie is changing up the guard of its global R&D organization as Thomas Hudson, M.D., retires. He will be replaced by Roopal Thakkar, M.D. …See details»
Aktis Oncology - Craft
Aktis Oncology is a biotechnology company that discovers and develops radiopharmaceuticals to treat a range of solid tumor cancers. It develops alpha radiotherapies and also generates …See details»
Aktis Oncology - Overview, News & Similar companies - ZoomInfo
May 29, 2024 www.aktisoncology.com. Revenue $6.8 Million. Industry Business Services General Business Services . Most Recent Scoops. Jul 9 2024. Lateral Move. May 30 2024. …See details»
Aktis Oncology Expands its Board of Directors with …
Jun 13, 2024 This approach would enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Aktis Oncology also has a strategic collaboration with Eli Lilly and Company. To learn more about …See details»
AKTIS ONCOLOGY ENTERS INTO STRATEGIC …
May 21, 2024 Aktis to receive a $60 million upfront payment for the collaboration in addition to an equity investment by Lilly; Aktis also eligible for milestone payments of up to $1.1 billion and royalties on ...See details»
AKTIS ONCOLOGY ENTERS INTO STRATEGIC COLLABORATION …
May 21, 2024 To learn more about Aktis Oncology, visit www.aktisoncology.com. MEDIA CONTACT Terri Clevenger ICR Westwicke 203 682-8297 [email protected] INVESTOR …See details»
AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL …
Aug 25, 2022 Funding to develop proprietary targeted alpha radiopharmaceutical pipeline for the treatment of highly prevalent cancers. CAMBRIDGE, Mass., Aug. 25, 2022 /PRNewswire/ -- …See details»
AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …
Sep 30, 2024 To learn more about Aktis Oncology, visit www.aktisoncology.com. MEDIA CONTACT Terri Clevenger ICR Westwicke 203-682-8297 [email protected] INVESTOR …See details»
AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL …
Aug 25, 2022 Funding to develop proprietary targeted alpha radiopharmaceutical pipeline for the treatment of highly prevalent cancers. Cambridge, MASS. (August 25, 2022) — Aktis …See details»
Aktis Oncology Announces $72M Series A Financing To Advance ...
CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad …See details»
AKTIS ONCOLOGY ANNOUNCES PRESENTATION OF THE FIRST …
Oct 24, 2024 AKY-1189 is a novel Nectin-4 targeted radiopharmaceutical product candidate demonstrating substantial tumor uptake across several solid tumor types and is progressing in …See details»
Aktis Oncology enters into strategic collaboration with Lilly to ...
May 21, 2024 To learn more about Aktis Oncology, visit www.aktisoncology.com. SOURCE: Aktis Oncology. Post Views: 20,800. Any Word All Words Exact Phrase. Any Word All Words …See details»
Join Us | Aktis Oncology
Aktis employees will only email you from an official @AktisOncology.com email account. Our applicant tracking system, ADP, may also send some confirmation or notification emails, but …See details»
Aktis Oncology Announces Actinium-225 Supply Agreements with …
Aug 23, 2022 Partnerships with NorthStar Medical Radioisotopes, Niowave, and TerraPower to Support Advancement of Targeted Alpha Radiopharmaceutical Pipeline to Treat a Broad …See details»